Santhera Pharmaceuticals AG, of Pratteln, Switzerland, said it entered a CHF15 million (US$15.04 million) credit line facility. It is also preparing for the issuance of up to 500,000 registered shares in a private placement managed by Mirabaud Securities (Geneva). In addition, Santhera is considering various options to monetize certain assets, which would provide for additional nondilutive funding.